Phase 4 Osteoporosis Trial, Recruiting NCT06059222 Sponsor: University of Aarhus Condition: Osteoporosis
Back to Osteoporosis

Phase 4 Osteoporosis Trial, Recruiting

NCT06059222
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women who have been through menopause for at least two years
  • Women whose bone density scan shows a T-score below -2.5 at the lower spine, hip, or upper thigh bone (indicating osteoporosis)
  • Women who have had a bone fracture in the last 3 years at the spine, hip, pelvis, shoulder, or forearm, occurring after the age of 50

Who may not be able to join:

  • Women who have taken any osteoporosis medications, including hormone replacement therapy, within the last 5 years
  • Women who have a disease that directly affects bone metabolism (confirm with trial site)
  • Women with certain health conditions known to affect bone health, such as uncontrolled overactive thyroid, liver problems, rheumatic disease, severe chronic lung disease (COPD), problems with the pituitary gland, or Cushing's disease
  • Women currently taking steroid tablets or injections (such as prednisolone) on an ongoing basis
  • Women whose kidneys are not working well enough (based on a specific blood test measuring kidney function)
  • Women who cannot take the medication zoledronate for any medical reason
  • Women who cannot take the medication romosozumab for any medical reason
  • For those who may have a small bone sample taken (biopsy): women who cannot have local anaesthetic for any medical reason
  • For those who may have a small bone sample taken (biopsy): women who cannot take the antibiotics tetracycline or doxycycline for any medical reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Bente Langdahl, MD, Professor, DMSc, PhD,, Department of Endocrinology and Internal medicin, Aarhus University Hospital

Phone: 78450000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
2 October 2023
Est. completion
31 August 2030

Where this trial is recruiting

🇩🇰 Denmark

Primary endpoints

Change in total hip BMD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov